Cross

Crosslink Therapeutics is a biotechnology company focused on developing next-generation cancer therapies by leveraging the unique biochemical environment of solid tumors. The company's core technology centers on a modular biologic domain engineered to recognize and assemble therapeutics in response to highly elevated levels of extracellular adenosine triphosphate (eATP), a hallmark of the tumor microenvironment. This platform is designed to improve tumor-specific targeting and enhance the activity of various therapeutic modalities, including antibody-drug conjugates (ADCs) and radioligand therapies. By utilizing eATP as a trigger for localized assembly, Crosslink aims to create first-in-class treatments that maximize efficacy while minimizing off-target toxicity.